「Pneumococcus」の版間の差分
ナビゲーションに移動
検索に移動
Vaccipedia.admin (トーク | 投稿記録) |
Vaccipedia.admin (トーク | 投稿記録) |
||
89行目: | 89行目: | ||
|- | |- | ||
!2009<br>平成21 | !2009<br>平成21 | ||
− | | ||Approved<br>2mo≤ ≤9yr|| || || | | + | | ||Approved<br> 2mo≤ ≤9yr|| || || | |
|- | |- | ||
!2010<br>平成22 | !2010<br>平成22 | ||
− | | ||Routinized<br>2mo≤ ≤60mo (<5yr)|| || || | | + | | ||Routinized<br> 2mo≤ ≤60mo (<5yr)|| || || | |
|- | |- | ||
!2013<br>平成25 | !2013<br>平成25 | ||
− | | ||Terminated and switched to PCV13||Approved<br>2mo≤ <6yr<br>Routinized<br>2mo≤ ≤60mo (<5yr)|| || | | + | | ||Terminated and switched to PCV13||Approved<br> 2mo≤ <6yr<br>Routinized<br> 2mo≤ ≤60mo (<5yr)|| || | |
|- | |- | ||
!2014<br>平成26 | !2014<br>平成26 | ||
− | |Routinized<br>at 65yr<br>or 60-64yr with specific chronic conditions|| ||Approved<br>65yr≤ at risk of IPD|| || | | + | |Routinized<br>at 65yr<br>or 60-64yr with specific chronic conditions|| ||Approved<br> 65yr≤ at risk of IPD|| || | |
|- | |- | ||
!2020<br>令和2 | !2020<br>令和2 | ||
− | | || ||Approved<br>6yr≤ at risk of IPD|| || | | + | | || ||Approved<br> 6yr≤ at risk of IPD|| || | |
+ | |- | ||
+ | !2022<br>令和4 | ||
+ | | || || ||Approved<br> elderly<br> or adults at risk of IPD|| | | ||
+ | |- | ||
+ | !2023<br>令和5 | ||
+ | | || || ||Approved<br> 2mo≤|| | | ||
|} | |} | ||
<nowiki>*</nowiki>Table updated on 25th Aug 2023 | <nowiki>*</nowiki>Table updated on 25th Aug 2023 |
2023年8月25日 (金) 15:17時点における版
Navigation Menu |
General issues of Vaccine | |||||||
---|---|---|---|---|---|---|---|
|
General issues of Travel med. | ||||||||
---|---|---|---|---|---|---|---|---|
|
Immunology | |||||||
---|---|---|---|---|---|---|---|
|
Epi & Stats | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Virus | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
COVID-19 | |||||
---|---|---|---|---|---|
|
Bacteria | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Rickettsia | |||||
---|---|---|---|---|---|
|
Protozoa | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Fungi | |||||||
---|---|---|---|---|---|---|---|
|
Nematode (roundworm) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Trematode (fluke, distoma) | |||||||
---|---|---|---|---|---|---|---|
|
Cestode (tapeworm) | ||||||
---|---|---|---|---|---|---|
|
Medical Zoology | ||||||||
---|---|---|---|---|---|---|---|---|
|
目次
epidemiology
- 1.19mi. deaths in 2016
- 197.05 mil. episodes in 2016
- the leading cause of lower respiratory infections followed by H. influenzae, influenza /B and RS virus
- 50% of pneumococcal deaths in India, Nigeria, DRC and Pakistan
serotype
- all serotypes known more than 90 are pathogenic for human
- differentiation of serotypes is important for epidemiology
antimicrobial resitance
- first reported in late 1960s
Vaccine
- PPSV does not induce T-cell dependent immunity
- PCV induces T-cell dependent immunity
- new product "Pneumosil" from India
- 10-valent
- serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, 23F
- the reason why PCV13 for older population failed to show persistent efficacy against IPD in the U.S. may be contributed by spread of PCV13 for children which has caused serotype substitutions in community
History of Pneumococcal vaccines in Japan
Brand name | Approval for children | Introduction to childhood routine immunization | Approval for adults | Introduction to adult routine immunization | Note | |
---|---|---|---|---|---|---|
PPSV23 | ニューモバックスNP Pneumovax NP |
1988(昭和63年) ≥ 2 y/o |
N/A† | 1988(昭和63年) | 2014(平成26年) only for all 65 y/o or 60-64 with specific conditions† | |
PCV7 | プレベナー Prevenar |
2009(平成21年) | 2010(平成22年) | N/A | N/A | Sales terminated and switched to PCV13 in 2013 |
PCV13 | プレベナー13 Prevenar 13 |
2013(平成25年) | 2013(平成25年) | 2014(平成26年)≥ 65 y/o 2020(平成28年) people at high risk of IPD irrespective of age |
N/A | |
PCV15 | バクニュバンス Vaxneuvance |
2023(令和5年) | N/A as of 2023 | 2022(令和4年) people at high risk of IPD irrespective of age | N/A | |
PCV20 | Under review as of 2023 |
†covered by Public Health Insurance for asplenia
*Table updated on 24th Aug 2023
Year | PPSV23 Pneumovax NP |
PCV7 Prevenar |
PCV13 Prevenar13 |
PCV15 Vaxneuvance |
PCV20 |
---|---|---|---|---|---|
1988 昭和63 |
Approved 2yr≤ Covered for asplenia by Public Health Insurance |
||||
2009 平成21 |
Approved 2mo≤ ≤9yr |
||||
2010 平成22 |
Routinized 2mo≤ ≤60mo (<5yr) |
||||
2013 平成25 |
Terminated and switched to PCV13 | Approved 2mo≤ <6yr Routinized 2mo≤ ≤60mo (<5yr) |
|||
2014 平成26 |
Routinized at 65yr or 60-64yr with specific chronic conditions |
Approved 65yr≤ at risk of IPD |
|||
2020 令和2 |
Approved 6yr≤ at risk of IPD |
||||
2022 令和4 |
Approved elderly or adults at risk of IPD |
||||
2023 令和5 |
Approved 2mo≤ |
*Table updated on 25th Aug 2023